Rather & Kittrell’s GSK GSK Stock Holding History

Rather & Kittrell’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-88	Closed	-$4K	–	150
2021 Q4	$4K	Buy	+88	New	+$4.58K	﹤0.01%	267

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Rather & Kittrell's GSK Position: Q1 2022 in Review

Rather & Kittrell sold out of GSK (GSK) in Q1 2022, closing a stake of 88 shares — an estimated $4K sold.

Rather & Kittrell first reported a position in GSK in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 929 funds tracked by Wall St. Rank hold GSK as of Q1 2022.

Rather & Kittrell reported no remaining GSK position as of Q1 2022 after selling out during the quarter.
Rather & Kittrell sold 88 GSK shares in Q1 2022, an estimated $4K.
Rather & Kittrell first reported a position in GSK in Q4 2021 and held it in 1 quarter.
Rather & Kittrell's GSK position peaked at $4K in Q4 2021.
929 funds tracked by Wall St. Rank held GSK as of Q1 2022.

Based on Rather & Kittrell's 13F filing for Q1 2022, filed 10 May 2022.